In vitro studies demonstrated that targeting CD38 on AML by a blocking antibody facilitates leukemic cell removal by immune cells and inhibits leukemic blast metabolism, impeding mitochondrial transfer from mesenchymal to leukemic cells [88], providing a rationale for its use in AML. The gene discussed is CD38; the disease is acute myeloid leukemia.